These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

270 related articles for article (PubMed ID: 10544903)

  • 21. Two daily subcutaneous injections of fragmin as compared with intravenous standard heparin in the treatment of deep venous thrombosis (DVT).
    Bratt G; Aberg W; Johansson M; Törnebohm E; Granqvist S; Lockner D
    Thromb Haemost; 1990 Dec; 64(4):506-10. PubMed ID: 1964751
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Subcutaneous adjusted-dose unfractionated heparin vs fixed-dose low-molecular-weight heparin in the initial treatment of venous thromboembolism.
    Prandoni P; Carnovali M; Marchiori A;
    Arch Intern Med; 2004 May; 164(10):1077-83. PubMed ID: 15159264
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparison of low-molecular-weight heparin, administered primarily at home, with unfractionated heparin, administered in hospital, and subcutaneous heparin, administered at home for deep-vein thrombosis.
    Belcaro G; Nicolaides AN; Cesarone MR; Laurora G; De Sanctis MT; Incandela L; Barsotti A; Corsi M; Vasdekis S; Christopoulos D; Lennox A; Malouf M
    Angiology; 1999 Oct; 50(10):781-7. PubMed ID: 10535716
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Economic evaluation of the use of nadroparin in the treatment of deep-vein thrombosis in Switzerland.
    Lloyd AC; Aitken JA; Hoffmeyer UK; Kelso EJ; Wakerly EC; Barber ND
    Ann Pharmacother; 1997; 31(7-8):842-6. PubMed ID: 9220041
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Aging and venous thromboembolism influence the pharmacodynamics of the anti-factor Xa and anti-thrombin activities of a low molecular weight heparin (nadroparin).
    Mismetti P; Laporte-Simitsidis S; Navarro C; Sié P; d'Azemar P; Necciari J; Duret JP; Gaud C; Decousus H; Boneu B
    Thromb Haemost; 1998 Jun; 79(6):1162-5. PubMed ID: 9657442
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Current trends in the treatment of deep venous thrombosis].
    Eichlisberger R; Frauchiger B; Jäger K
    Schweiz Rundsch Med Prax; 1994 Feb; 83(7):183-8. PubMed ID: 8184243
    [TBL] [Abstract][Full Text] [Related]  

  • 27. An exploratory trial of two dosages of a novel synthetic thrombin inhibitor (napsagatran, Ro 46-6240) compared with unfractionated heparin for treatment of proximal deep-vein thrombosis -- results of the European multicenter ADVENT trial.
    Bounameaux H; Ehringer H; Hulting J; Rasche H; Rapold HJ; Zultak M
    Thromb Haemost; 1997 Sep; 78(3):997-1002. PubMed ID: 9308743
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Low-molecular-weight heparin for the treatment of acute ischemic stroke.
    Kay R; Wong KS; Yu YL; Chan YW; Tsoi TH; Ahuja AT; Chan FL; Fong KY; Law CB; Wong A
    N Engl J Med; 1995 Dec; 333(24):1588-93. PubMed ID: 7477193
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Markers of hemostatic system activation during treatment of deep vein thrombosis with subcutaneous unfractionated or low-molecular weight heparin.
    Peternel P; Terbizan M; Tratar G; Bozic M; Horvat D; Salobir B; Stegnar M
    Thromb Res; 2002 Feb; 105(3):241-6. PubMed ID: 11927130
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Low molecular weight heparin (nadroparine) versus oral anticoagulant (acenocoumarol) in the long-term treatment of deep venous thrombosis: comparison of efficacy, safety and hospitalisation period in 105 patients.
    Mazokopakis EE; Vrentzos GE; Ganotakis ES
    Curr Med Res Opin; 2003; 19(6):565-6. PubMed ID: 14594529
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Relation between the time to achieve the lower limit of the APTT therapeutic range and recurrent venous thromboembolism during heparin treatment for deep vein thrombosis.
    Hull RD; Raskob GE; Brant RF; Pineo GF; Valentine KA
    Arch Intern Med; 1997 Dec 8-22; 157(22):2562-8. PubMed ID: 9531224
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Heparin and tranexamic Acid therapy may be effective in treatment-resistant chronic urticaria with elevated d-dimer: a pilot study.
    Asero R; Tedeschi A; Cugno M
    Int Arch Allergy Immunol; 2010; 152(4):384-9. PubMed ID: 20203527
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Physician-guided treatment compared with a heparin protocol for deep vein thrombosis.
    Elliott CG; Hiltunen SJ; Suchyta M; Hull RD; Raskob GE; Pineo GF; Jensen RL; Yeates S; Kitterman N
    Arch Intern Med; 1994 May; 154(9):999-1004. PubMed ID: 8179457
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A randomised trial of subcutaneous low molecular weight heparin (CY 216) compared with intravenous unfractionated heparin in the treatment of deep vein thrombosis. A collaborative European multicentre study.
    Thromb Haemost; 1991 Mar; 65(3):251-6. PubMed ID: 1646490
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Randomized, prospective trial comparing bridging therapy using low-molecular-weight heparin with maintenance of oral anticoagulation during extraction of teeth.
    Bajkin BV; Popovic SL; Selakovic SD
    J Oral Maxillofac Surg; 2009 May; 67(5):990-5. PubMed ID: 19375008
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparison of six-month outcome of patients initially treated for acute deep vein thrombosis with a low molecular weight heparin Certoparin at a fixed, body-weight-independent dosage or unfractionated heparin.
    Harenberg J; Riess H; Büller HR; Brom J; Weidinger G; Huisman MV
    Haematologica; 2003 Oct; 88(10):1157-62. PubMed ID: 14555312
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Continuous intravenous infusion of a low-molecular-weight heparin during allogenic haematopoietic stem-cell transplantation.
    Boeras A; Lambert C; Ferrant A; van den Neste E; Hermans C
    Blood Coagul Fibrinolysis; 2008 Oct; 19(7):735-7. PubMed ID: 18832921
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A pilot study of subcutaneous recombinant hirudin (HBW 023) in the treatment of deep vein thrombosis.
    Schiele F; Vuillemenot A; Kramarz P; Kieffer Y; Soria J; Soria C; Camez A; Mirshahi MC; Bassand JP
    Thromb Haemost; 1994 May; 71(5):558-62. PubMed ID: 8091380
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Treatment of deep vein thrombosis with continuous intravenous infusion of LMWH in children--an alternative to subcutaneous application when needed.
    Blatný J; Fiamoli V
    Vnitr Lek; 2009 Mar; 55(3):227-32. PubMed ID: 19378852
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Low molecular weight heparin (dalteparin) is equally effective as unfractionated heparin in reducing coagulation activity and perfusion abnormalities during the early treatment of pulmonary embolism.
    Schutgens RE; Esseboom EU; Snijder RJ; Haas FJ; Verzijlbergen F; Nieuwenhuis HK; Lisman T; Biesma DH
    J Lab Clin Med; 2004 Aug; 144(2):100-7. PubMed ID: 15322504
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.